GRI Bio, Inc. Common Stock

Day range

$1.70 – $1.83

Open

$1.79

Prev close

$1.82

Volume

21.85K

Market cap

$3.72M

Shares out

2.19M

P/E

—

P/S

—

P/B

0.36

P/FCF

—

ROE

-94.0%

ROA

-84.9%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 13, 2026

• Annual meeting resultsNov 4, 2026

  The following actions were taken at the Annual Meeting: Proposal 1 Election of ... nominees to the Company's Board of Directors ... Proposal 2 Ratification of the appointment of WithumSmith+Brown, PC ... Proposal 3 Approval of an amendment and restatement ... [and] Proposal 4 Approval of any postponement or adjournment of the Annual Meeting.

• Investor presentationSep 8, 2026

  On September 8, 2026, GRI Bio, Inc. (the "Company") posted an updated corporate presentation to the Company's website at www.gribio.com/investors/events-presentations/ which is included as Exhibit 99.1 to this Current Report on Form 8-K.

• Regulatory decisionJun 18, 2026

  the U.S. Food and Drug Administration has granted Orphan Drug Designation to GRI-0621 for the treatment of idiopathic pulmonary fibrosis

• Public offeringJan 30, 2026

  On January 29, 2026, the Company entered into an Amendment No. 1 to At The Market Offering Agreement (the "Amendment") with Wainwright, effective as of January 28, 2026, to increase the aggregate offering price of the Shares that the Company may sell in the ATM Offering from $10,000,000 to up to the dollar amount of Shares registered on the prospectus supplement pursuant to which the ATM Offering is being made. In connection with the Amendment, on January 29, 2026, the Company filed a prospectus supplement with the Commission to increase the maximum number of Shares issuable in the ATM Offering to up to an aggregate of $60,000,000.

• Stock splitJan 21, 2026

  On January 21, 2026, GRI Bio, Inc. (the "Company") filed with the Secretary of State of the State of Delaware an amendment (the "Certificate of Amendment") to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a ratio of 1-for-28 (the "Reverse Stock Split"). Pursuant to the Certificate of Amendment, the Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on January 23, 2026 (the "Effective Time") and shares of the Company's Common Stock are expected to begin trading on a post-split basis at the open of trading on The Nasdaq Capital Market on January 26, 2026. At the Effective Time, every twenty-eight (28) shares of the Company's issued and outstanding shares of Common Stock will be automatically converted into one (1) share of Common Stock.

Days to cover

1.6

Short interest

66.51K

Avg volume

42.74K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
  positiveGlobeNewswire Inc.· Jul 31, 2025
• Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
  positiveGlobeNewswire Inc.· Jan 13, 2025
• GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
  positiveGlobeNewswire Inc.· Dec 23, 2024
• GRI Bio Announces Exercise of Warrants
  positiveGlobeNewswire Inc.· Oct 21, 2024
• GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series - GlobeNewswire
  positiveGlobeNewswire Inc.· Jul 15, 2024